ArticlePharmaceutical research2018
Iron-Based Metal-Organic Frameworks as a Theranostic Carrier for Local Tuberculosis Therapy.
Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 75 citations in OpenAlex.
- The Application of Metal-Organic Frameworks as Drug Delivery Systems: From the Perspective of Molecular Dynamics Simulations.MedComm · 2026Review
- Nanomaterials in COPD: Emerging Therapeutic and Diagnostic Frontiers with a Focus on Metal-Organic Frameworks.International journal of molecular sciences · 2025Review
- Synthesis, Characterization, and Toxicity Evaluation of Size-Dependent Iron-Based Metal-Organic Frameworks.Nanomaterials (Basel, Switzerland) · 2025Article
- Magnetic Nanoparticles Combined With Pulsed Electromagnetic Field Alleviate Chondrocyte Necroptosis in Osteoarthritis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Iron, Copper, and Zinc Homeostasis in the Battle between Macrophage andCurrent medicinal chemistry · 2025Review
- Metal-organic frameworks in drug delivery: engineering versatile platforms for therapeutic applications.RSC advances · 2024Review
- Slowing Down the "Magic Bullet": Encapsulation of Imatinib in Fe-MOF for Cardiotoxicity Reduction and Improvement in Anticancer Activity.Molecules (Basel, Switzerland) · 2024Article
- Microwave-Responsive Metal-Organic Frameworks (MOFs) for Enhanced In Vitro Controlled Release of Doxorubicin.Nanomaterials (Basel, Switzerland) · 2024Article
- Functional MOF-Based Materials for Environmental and Biomedical Applications: A Critical Review.Nanomaterials (Basel, Switzerland) · 2023Review
- Fe-Based Metal Organic Frameworks (Fe-MOFs) for Bio-Related Applications.Pharmaceutics · 2023Review
- Metal-Organic Framework-Based Nanomedicines for the Treatment of Intracellular Bacterial Infections.Pharmaceutics · 2023Review
- Size-Controlled Preparation of Docetaxel- and Curcumin-Loaded Nanoemulsions for Potential Pulmonary Delivery.Pharmaceutics · 2023Article
- Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects.Frontiers in drug delivery · 2023Review
- Multinuclear MRI in Drug Discovery.Molecules (Basel, Switzerland) · 2022Review
- Upconversion Nanostructures Applied in Theranostic Systems.International journal of molecular sciences · 2022Review
- Biomedical Applications of Metal-Organic Frameworks for Disease Diagnosis and Drug Delivery: A Review.Nanomaterials (Basel, Switzerland) · 2022Review
- Zinc-Based Metal-Organic Frameworks in Drug Delivery, Cell Imaging, and Sensing.Molecules (Basel, Switzerland) · 2021Review
- Metal-organic frameworks for advanced drug delivery.Acta pharmaceutica Sinica. B · 2021Review
- Studies on metal-organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension.Scientific reports · 2021Article
- Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies.Emerging topics in life sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
purposeThe purpose of the study was initial evaluation of applicability of metal organic framework (MOF) Fe-MIL-101-NH
methodsFe-MIL-101-NH
resultsMOF particles were loaded with 12% of isoniazid. The particle size (3.37-6.45 μm) depended on the micronization method used. The proposed drug delivery system can also serve as the MRI contrast agent. The drug dissolution showed extended release of isoniazid. MOF particles accumulated in the L929 fibroblast cytoplasmic area, suggesting MOF release the drug inside the cells. The cytotoxicity confirmed safety of MOF system.
conclusionsThe application of MOF for extended release inhalable system proposes the novel strategy for delivery of standard antimycobacterial agents combined with monitoring of their distribution within the lung tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.